Search Results
Your search for ,NOt matches 22378 pages
Showing 451 - 500Recent Rates of Systemic Treatment for Metastatic NSCLC in Older Adults
In a cohort study reported in JAMA Oncology, Fox et al found that approximately half of older patients with metastatic non–small cell lung cancer (NSCLC) have received systemic therapy in the United States in recent years. Study Details The population-based study used linked Surveillance...
Meta-Analysis Explores Impact of Ovarian Function Suppression on Breast Cancer Recurrence and Survival
In a patient-level meta-analysis reported in The Lancet, the Early Breast Cancer Trialists’ Collaborative Group found that ovarian function suppression (OFS) with ablation or drugs was associated with reduced 15-year risk of recurrence or death irrespective of chemotherapy or tamoxifen use in...
I’m Young and Have Advanced Neuroendocrine Carcinoma of the Rectum
Eight years ago, I was 33 years old, and my main health concern was a diagnosis of ankylosing spondylitis, a form of arthritis that causes stiff, painful joints in the spine. Having a chronic disease made me pay close attention to any changes in my health, so when I noticed blood in my stool, I...
Patient Care Is Not What We Do, But What Patients Perceive
In modern health care, patient care is often defined by clinical actions such as diagnoses made, treatments delivered, and protocols followed. Clinicians are trained to prioritize technical accuracy, evidence-based interventions, and measurable outcomes. However, an equally critical and often...
New ASCO Guideline Fills Gap in Guidance on Rapidly Evolving Treatment Options in Thyroid Cancer
ASCO has issued a new clinical practice guideline on the use of systemic therapy for treatment of different types of thyroid cancer, a field that has changed substantially in recent years.1 “Despite a rather rapidly evolving field of targeted and nontargeted systemic agents in the management of...
From Hawaii to Health AI: A Career at the Intersection of Oncology, Data Science, and Clinical Knowledge
Raised in Lahaina, Hawaii, before wildfires destroyed much of the small tourist town in 2023, Travis Zack, MD, PhD, took an atypical path into medicine. His journey has been shaped by family, mentors, a personal experience with cancer, and a growing interest in how artificial intelligence (AI) can...
Could AI Be Licensed to Practice Oncology?
Is artificial intelligence (AI) poised to practice medicine? It may be already. Earlier this year, the state of Utah allowed Doctronic, a health technology company using AI to make clinical decisions autonomously, to renew prescriptions for patients who request the service. Although Utah’s pilot...
Long-Term Risks Revealed for Older Survivors of Childhood Cancers
Survivors of childhood cancer who reach the age of 50 and beyond show continued elevated risks for premature mortality, subsequent cancers, and other chronic health conditions, according to a report published in the Journal of Clinical Oncology.1 When compared with the general population or sibling ...
Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures
Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occurring in low- and middle-income countries.1 Delays in obtaining an accurate diagnosis,...
Can Physical Activity Reduce Cancer-Related Fatigue?
Greater physical activity—particularly walking—may reduce fatigue and improve quality of life in patients with colorectal cancer, with stronger associations observed in nonmetastatic disease. These findings were demonstrated in a longitudinal analysis of the ColoCare Study population presented by...
LLM-Based Preoperative Patient Communications Alleviate Anxiety, Physician Workload
Researchers from the Department of Urology at Fudan University Shanghai Cancer Center evaluated artificial intelligence (AI)–assisted communications in the preoperative setting to assess its impact on patient anxiety and clinician workload. The performance of the model was assessed in a...
De-escalation, Recovery, and Robotic Surgery in Breast Cancer Care
At the American Society of Breast Surgeons (ASBrS) 27th Annual Meeting, investigators presented new findings on breast cancer surgery, postoperative recovery, and radiation treatment planning. Among the many sessions, several studies were presented during a media briefing earlier this month and are ...
Tiragolumab/Atezolizumab and Chemotherapy Fails in Advanced Nonsquamous NSCLC
As reported in JAMA Oncology by Socinski et al, the phase III SKYSCRAPER-06 trial showed no progression-free or overall survival benefit with tiragolumab, a monoclonal antibody targeting T-cell immunoreceptor with Ig and ITIM domains (immunoreceptor tyrosine-based inhibitory motifs) (TIGIT), plus...
AI Pathology Framework for Biological Understanding of Tumors
An agentic artificial intelligence (AI) framework may help researchers gain a better understanding of hidden biological information of tumors, according to a study published in Nature Medicine. “SPARK helps to refine diagnoses, stratify patients more reliably, and make more precise treatment...
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alone. Interim results from the CLIMATE study found post-orchiectomy plasma miR-371a-3p (miR-371), a...
‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer improves patient outcomes. Clinicians should therefore proceed with caution until such evidence...
Advanced CKM Syndrome Associated With Greater Cancer Risk
Advanced cardiovascular-kidney-metabolic (CKM) syndrome may be associated with an increased risk of developing cancer, according to findings from a Japanese study published in Circulation: Population Health and Outcomes. “The study findings suggest that it is important to consider not only...
Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases
In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intravenous (IV) oxaliplatin, both combined with fluorouracil/leucovorin (LV5FU2), after curative-intent...
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings
Patients diagnosed with metastatic breast cancer and non–small cell lung cancer (NSCLC) had longer survival compared to national benchmarks when treated in independent community oncology practices, according to a new study commissioned by the Community Oncology Alliance (COA) and conducted by...
Association of Body Size and Bladder Cancer Risk
In a study—The Pooling Project of Prospective Studies of Diet and Cancer—reported in the Journal of Clinical Oncology, Milne et al in the National Cancer Institute Cohort Consortium found that increased body size is associated with increased risk of bladder cancer among men, but not among women....
Can PFAS Exposure Raise ALL Risk?
Early exposure to per- and polyfluoroalkyl substances (PFAS), a group of widely used compounds known as “forever chemicals,” may be associated with a higher risk of developing acute lymphoblastic leukemia (ALL), according to findings published by Vieira et al in the Journal of Exposure Science...
Atezolizumab in Alveolar Soft Part Sarcoma: Long-Term Follow-up
As reported in the Journal of Clinical Oncology by Chen et al, extended follow-up of the pivotal phase II trial of atezolizumab in patients with alveolar soft part sarcoma (ASPS) showed continued benefit of atezolizumab treatment. Study Details In the U.S. multicenter trial, 53 patients received...
Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma
At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib improved progression-free survival, produced a higher objective response rate, and showed a trend...
Can Pesticide Exposure Increase Early-Onset Colorectal Cancer Risk?
A new study has identified for the first time the exposome footprint—the set of environmental and lifestyle exposures—for colorectal cancer occurring in patients younger than age 50 through epigenetic signatures. By comparatively analyzing DNA methylation patterns in patients under and over 50, the ...
Metabolic Tumor Volume Predicts CAR T-Cell Therapy Response in LBCL
Positron-emission tomography (PET)-based metabolic tumor volume could serve as a significant measure of response to chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma, according to the results of a study published in The Journal of Nuclear Medicine. Metabolic...
AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS
Monitoring for relapse with an artificial intelligence (AI)-powered peripheral blood-based tool called AlloHeme demonstrated greater sensitivity in predicting relapse after hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) than ...
Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC
As reported in the Journal of Clinical Oncology by Li et al, long-term follow-up of a Chinese phase II trial (TRUST-I) showed prolonged activity with taletrectinib in patients with ROS1 mutation–positive non–small cell lung cancer (NSCLC). Study Details In the multicenter trial, 173 patients had...
Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer
In a phase Ib/II study (OrigAMI-1) reported in the Journal of Clinical Oncology, Oberstein et al found that the EGFR-MET bispecific antibody amivantamab-vmjw showed activity when used as monotherapy in patients with chemorefractory RAS/BRAF wild-type metastatic colorectal cancer. Study Details In...
Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age
Investigators have found that overdiagnosis of prostate cancer through prostate-specific antigen (PSA) screening is low in younger men—but rises sharply with age. The study, which aimed to estimate the impact of age on overdiagnosis of prostate cancer 15 years after screening stops, analyzed...
Global Review Shows Impact of Exposure to Air Pollution on Cancer Risk and Mortality
Long-term exposure to air pollution significantly increases both the risk of developing cancer and the likelihood of dying from the disease, according to a new global evidence report released by the Union for International Cancer Control (UICC), titled Clean air in cancer control: An overview of...
Do Political Beliefs Shape Views on Clinical Trials in Cancer?
In a cross-sectional study published in JAMA Network Open, political ideology was associated with clinical trial skepticism, with conservative identification linked to higher odds of endorsing such views. Among cancer survivors, Chido-Amajuoyi et al similarly observed greater skepticism among...
RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer
The treatment landscape for advanced pancreatic cancer is shifting. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up. In mid-April, Revolution Medicines announced positive results from its phase III RASolute 302 clinical trial of daraxonrasib, an ...
ACP Issues New Controversial Breast Cancer Screening Guidelines: ACR and SBI Counter With Statement
New guidance from the American College of Physicians (ACP) says all average-risk females between ages 50 and 74 should receive biennial screening mammography for breast cancer, and that females between the ages of 40 and 49 should discuss with their doctor their risk for breast cancer and the...
Long-Time ASCO Member Philip A. Salem, MD, Honored for Medical Excellence, Leadership, and Compassion
On January 29, 2026, Baylor St. Luke’s Medical Center and the Dan L Duncan Comprehensive Cancer Center formally dedicated the Philip A. Salem, MD Conference Center at the O’Quinn Medical Tower. On this occasion, both the governor of Texas and the mayor of the city of Houston made proclamations,...
Novel Therapies Improve Outcomes Across Hematologic Malignancies
In an effort to help clinicians stay current with rapidly evolving hematology-oncology literature, we are providing these concise, clinically focused summaries of important peer-reviewed studies. These summaries are intended to highlight key findings, study design, and outcomes that may inform...
Cancer Researcher Awarded Sjöberg Prize For Describing Tumors’ Evolution
This year’s Sjöberg Prize of $1 million U.S. dollars was awarded to a British cancer researcher who has provided fundamental knowledge about evolution in tumors. Professor Charles Swanton, FRCP, BSc, PhD, at the Francis Crick Institute in London, described how tumors’ mutations arise and develop....
Update to Patient–Clinician Communication Guideline Provides Recommendations on Telehealth, Boundary-Setting
ASCO has updated its guideline on patient–clinician communication, providing recommendations on a range of best practices for explaining treatment options and goals of care, conversing with patients’ support networks, communicating among care team members, and setting boundaries.1 The update to the ...
GLP-1 RAs May Reduce Mortality In Some Patients With Colorectal Cancer and Comorbid Obesity: Real-World Outcomes
Colon cancer is among the leading causes of cancer-related morbidity and mortality worldwide, with alarming increases in incidence and mortality among younger adults. Although the exact causes of these increases are unknown, lifestyle, including poor diets, sedentary habits, smoking, and alcohol...
Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in BRCA/ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 and/or ATM alterations.1...
What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Debate
Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of trials are international studies investigating T-DXd as a potential treatment option for eligible...
AMA Data Show Nearly 50% of Surveyed Oncologists Reported Burnout in 2025
New data from the American Medical Association (AMA) show physician burnout continuing to decline nationwide, but significant differences across medical specialties underscore the need for more targeted solutions within health systems. In 2025, 41.9% of physicians reported experiencing at least one ...
Long-Term Immunotherapy for Alveolar Soft Part Sarcoma
Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard 2 years, according to results from a phase II clinical trial presented at the American...
Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
In a Chinese phase II trial (EC-CRT-002) reported in the Journal of Clinical Oncology, Chen et al found that the addition of the anti–PD-1 monoclonal antibody tislelizumab without maintenance cycles to induction chemotherapy and concurrent chemoradiotherapy significantly improved progression-free...
Unique Phase I NSCLC Trial Sites Decreasing in United States
The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant consolidation of studies to only high trial volume sites in the country, according to the results of a...
Lyudmila A. Bazhenova, MD, on ROS1-Positive NSCLC: Taletrectinib in TKI-Naive Patients
Lyudmila A. Bazhenova, MD, of the University of California, San Diego, presents updated data from the phase II TRUST-I and TRUST-II trials. With approximately 3 years of follow-up in the pooled analysis, investigators now conclude that the next-generation, selective ROS1 tyrosine kinase inhibitor...
Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
Early-onset of immune checkpoint inhibitor (ICI)–related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5212). The researchers suggested...
First-Line Zongertinib in Advanced HER2-Mutant NSCLC
In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell lung cancer (NSCLC). As noted by the investigators, zongertinib is an oral, irreversible tyrosine...
Exposure to Wildfire Smoke May Be Linked to Increased Risk of Developing Several Types of Cancer
Exposure to wildfire smoke was associated with a significantly increased risk of lung, colorectal, breast, bladder, and blood cancers, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 6252). Although it’s known that...
Intralesional Nivolumab May Be Effective Against Precancerous Oral Lesions
Injecting the PD-1 inhibitor nivolumab directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery, according to research from a phase I clinical trial (ClinicalTrials.gov identifier NCT05327270) presented at the American Association for Cancer ...
Methylation-Based AI Model Classifies Tumors of Unknown Origin
An artificial intelligence (AI) model using DNA methylation patterns was able to classify tumors of unknown origin with high accuracy, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 3869). “One of the most...
